ClinicalTrials.gg
CompletedNCT06945458BroADenUpdated Jan 26, 2026

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

A Phase 1 interventional study of KT-621 in Atopic Dermatitis, sponsored by Kymera Therapeutics, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Kymera Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
447th of 544
22 · median 96
Started
2025
with 40 others
Phase 1
82 of 639
10 open now
Registered
585th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 447th largest by enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 82 in phase 1, and was the 585th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • KT621
  • STAT6
  • STAT6 degrader
  • Targeted protein degrader
  • Phase 1
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 18 to 55 years (inclusive) at the time of screening
  • Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures
  • Participants must have had chronic atopic dermatitis (AD) for at least 1 year before Screening.
  • Moderate to very severe eczema as determined by Eczema Area and Severity Index (EASI) score of at least 16 at the baseline visit.
  • A validated Investigator Global Assessment (vIGA) score of at least 3 at the baseline visit, indicating moderate to severe AD.
  • At least 10% body surface area (BSA) of AD involvement at the baseline visit.
  • Weekly average Peak Pruritus Numeric Rating Scale (NRS) of at least 4 at the baseline visit.
  • Documented history within 6 months prior to baseline visit of either inadequate response or to topical medications for AD.
  • Application of stable dose of moisturizer at least twice daily for at least 7 consecutive days immediately prior to the baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, ophthalmological, or connective tissue diseases or disorders.
  • Participants who have any surgical or medical procedure planned during participation in the study.
  • Participants with a history of alcohol or substance abuse within the previous 2 years.
  • Participants who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
  • Participants whose results from clinical laboratory safety tests are outside the local reference range at Screening.
  • Participants who have been dosed with any drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.
  • Participants with a history of lack of response to any medication targeting interleukin (IL)-4, IL-13, and/or janus kinase (JAK)- signal transducer and activator of transcription (STAT) pathways (e.g. dupilumab, tralokinumab, upadacitinib, abrocitinib) at approved doses after at least 16 weeks of therapy.
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
  • Female participants of with a positive or undetermined pregnancy result at the Screening and baseline visits.
  • Participants with a known sensitivity to any of the components of KT-621.
  • Participants who are a member of the investigational team or his/her immediate family.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    KT-621

    Each participant receives daily oral doses of KT-621 throughout the 28-day treatment period.

    Drug: KT-621

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: From enrollment through the safety follow-up visit on Day 43

  2. Incidence of treatment-emergent potentially clinically-significant abnormalities in electrocardiogram (ECG) results, vital signs, or laboratory test results from the serum chemistry, hematology (with differential), chemistry, or coagulation panels.

    Time frame: From enrollment through the safety follow-up visit on Day 43

Secondary outcomes

  1. Plasma PK parameter estimates of KT-621 derived from plasma concentration-time data

    Trough concentrations taken at each visit before dosing, post-dose concentrations taken after dosing at Days 1 and 15.

    Time frame: From baseline visit through the safety follow-up visit on Day 43

Other outcomes

  1. KT-621 concentrations in skin

    Time frame: From baseline visit through the safety follow-up visit on Day 43

  2. Change in Eczema Area and Severity Index (EASI) score

    Time frame: From screening through the safety follow-up visit on Day 43

  3. Proportion of participants who achieve a validated Investigator Global Assessment (vIGA) score of 0 or 1 at scheduled clinic visits

    On a scale of 0 to 4, 0 being no inflammatory signs of AD, 4 being severe inflammatory signs of AD

    Time frame: From screening through the safety follow-up visit on Day 43

  4. Change from baseline in the Peak Pruritus Numeric Rating Scale (NRS) score

    Percent change from baseline

    Time frame: From baseline visit through the safety follow-up visit on Day 43

  5. Change from baseline in levels of signal transducer and activator of transcription 6 protein, in skin and in whole blood

    Time frame: From baseline visit through the safety follow-up visit on Day 43

  6. Change from baseline in the serum levels of Th2 biomarkers such as thymus and activation-regulated chemokine (TARC)

    Time frame: From baseline visit through the safety follow-up visit on Day 43

  7. Change from baseline through Week 4 in the serum levels of proinflammatory cytokines

    Time frame: From baseline visit through the safety follow-up visit on Day 43

  8. Change from baseline through Week 4 in messenger RNA transcriptome levels on the skin.

    Time frame: From baseline visit through the safety follow-up visit on Day 43

07

Study locations

12 sites
  • Kymera Investigative Site
    Birmingham, Alabama 35244, United States
  • Kymera Investigative Site
    Fountain Valley, California 92708, United States
  • Kymera Investigative Site
    Santa Monica, California 90404, United States
  • Kymera Investigative Site
    Boynton Beach, Florida 33436, United States
  • Kymera Investigative Site
    Hollywood, Florida 33024, United States
  • Kymera Investigative Site
    Tampa, Florida 33613, United States
  • Kymera Investigative Site
    Fargo, North Dakota 58078, United States
  • Kymera Investigative Site
    Dublin, Ohio 43016, United States
  • Kymera Investigative Site
    Springfield, Ohio 45505, United States
  • Kymera Investigative Site
    Tulsa, Oklahoma 74136, United States
  • Kymera Investigative Site
    Charleston, South Carolina 29420, United States
  • Kymera Investigative Site
    San Antonio, Texas 78213, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Nov 2025, 6 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 25, 2025
StartActual
Apr 17, 2025
Primary completionActual
Nov 10, 2025
CompletionActual
Nov 10, 2025
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06945458
Lead sponsor
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
Apr 17, 2025
Primary completion
Nov 10, 2025
Completion
Nov 10, 2025
Last update
Jan 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KT-621

Start the discussion